RxDoctor Payments Data

Mohamad Lazkani, MD

Interventional Cardiology · Phoenix, AZNPI 1174843403

Payments from drug & device makers

What this record shows

20 manufacturers reported payments, led by Edwards Lifesciences at 52.4% of the total.

$13,637in general payments, 2019–2025

Across 168 payments — averaging $81.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$7K
  • Abbott$2K
  • Boston Scientific$1K
  • Medical Device Business Services, Inc.$1K
  • Medtronic$915
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$301
  • plus $925 from 14 others
$1,054,920in research payments, 2019–2025

Across 137 payments — averaging $7700.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$1.1M

What the payments were for

  • Travel & lodging$6,23046%
  • Food & beverage$7,40854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,637 in reported general payments places this provider in the 55th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$128,701
Medicare patients
526
Services billed
912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$230,061
XareltoRivaroxaban31$27,780
Potassium Chloride53$2,469
Atorvastatin Calcium192$1,906
Metoprolol Succinate146$1,801
Rosuvastatin Calcium53$1,674
ClopidogrelClopidogrel Bisulfate85$1,406
Bumetanide24$1,008
Hydralazine Hcl26$996
Warfarin Sodium63$952
Metoprolol Tartrate150$921
Amlodipine Besylate108$813
Losartan Potassium68$751
Furosemide137$701
Lisinopril88$623

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →